在EMPEROR-Preserved试验中，终点定义对恩格列净治疗主要肾脏结局的影响。 - Suppr

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.

作者信息

Packer Milton, Zannad Faiez, Butler Javed, Filippatos Gerasimos, Ferreira Joao Pedro, Pocock Stuart J, Brueckmann Martina, Zeller Cordula, Hauske Sibylle, Anker Stefan D

机构信息

Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.

Imperial College, London, UK.

出版信息

Eur J Heart Fail. 2021 Oct;23(10):1798-1799. doi: 10.1002/ejhf.2334. Epub 2021 Aug 30.

DOI:10.1002/ejhf.2334

PMID:34459076

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9291539/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d1d/9291539/413e1c82dc5b/EJHF-23-1798-g001.jpg

相似文献

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.在EMPEROR-Preserved试验中，终点定义对恩格列净治疗主要肾脏结局的影响。

Eur J Heart Fail. 2021 Oct;23(10):1798-1799. doi: 10.1002/ejhf.2334. Epub 2021 Aug 30.

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.恩格列净对伴或不伴糖尿病的心力衰竭患者心血管和肾脏结局的影响：来自 EMPEROR-Reduced 试验的结果。

Circulation. 2021 Jan 26;143(4):337-349. doi: 10.1161/CIRCULATIONAHA.120.051824. Epub 2020 Nov 11.

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数降低的心力衰竭患者中的应用：EMPEROR-Reduced 和 DAPA-HF 试验的荟萃分析。

Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。

N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.在 EMPEROR-Preserved 试验中射血分数保留型心力衰竭患者的基线特征。

Eur J Heart Fail. 2020 Dec;22(12):2383-2392. doi: 10.1002/ejhf.2064.

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions.恩格列净治疗射血分数保留型心力衰竭的结局：使用类似 DELIVER 的终点定义。

Eur J Heart Fail. 2022 Aug;24(8):1400-1405. doi: 10.1002/ejhf.2558. Epub 2022 Jun 5.

Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.恩格列净在黑人与白人心力衰竭患者中的应用：EMPEROR汇总分析

Circulation. 2023 Jan 3;147(1):101-104. doi: 10.1161/CIRCULATIONAHA.122.062644. Epub 2022 Nov 7.

Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved.恩格列净在EMPEROR-Preserved研究中改善了射血分数保留的心力衰竭（HFpEF）的临床结局。

Nat Rev Cardiol. 2021 Nov;18(11):737. doi: 10.1038/s41569-021-00627-z.

Empagliflozin and Major Renal Outcomes in Heart Failure.恩格列净与心力衰竭的主要肾脏结局

N Engl J Med. 2021 Oct 14;385(16):1531-1533. doi: 10.1056/NEJMc2112411. Epub 2021 Aug 27.

Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.恩格列净对射血分数保留的慢性心力衰竭患者发病率和死亡率影响的评估：EMPEROR-Preserved 试验的原理和设计。

Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16.

引用本文的文献

Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease.慢性肾脏病患者射血分数保留的心力衰竭的病理生理联系及治疗意义

Biomedicines. 2024 Apr 30;12(5):981. doi: 10.3390/biomedicines12050981.

A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials.DAPA-HF 和 DELIVER 试验中心力衰竭患者应用赢者统计的肾脏结局分层。

Nat Med. 2024 May;30(5):1432-1439. doi: 10.1038/s41591-024-02941-8. Epub 2024 May 6.

The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.射血分数保留的心力衰竭的治疗与管理：治疗新见解

Card Fail Rev. 2024 Apr 3;10:e05. doi: 10.15420/cfr.2023.13. eCollection 2024.

Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side.钠-葡萄糖协同转运蛋白2抑制剂：从实验室到临床在非糖尿病肾病中的作用机制与疗效

J Clin Med. 2024 Feb 7;13(4):956. doi: 10.3390/jcm13040956.

Sodium-Glucose Cotransporter Protein 2 Inhibitors: Novel Application for the Treatment of Obesity-Associated Hypertension.钠-葡萄糖协同转运蛋白2抑制剂：治疗肥胖相关性高血压的新应用

Diabetes Metab Syndr Obes. 2024 Jan 26;17:407-415. doi: 10.2147/DMSO.S446904. eCollection 2024.

Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.钠-葡萄糖共转运蛋白 2 抑制剂治疗射血分数保留的心力衰竭和伴有或不伴有 2 型糖尿病的慢性肾脏病：叙事性综述。

Cardiovasc Diabetol. 2023 Nov 16;22(1):316. doi: 10.1186/s12933-023-02023-y.

Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials.射血分数保留的心力衰竭的药物治疗和合并症管理进展：来自临床试验的证据

Heart Fail Rev. 2024 Mar;29(2):305-320. doi: 10.1007/s10741-023-10338-x. Epub 2023 Aug 10.

SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review.用于2型糖尿病和慢性肾脏病患者的钠-葡萄糖协同转运蛋白2抑制剂：一项叙述性综述

Endocr Connect. 2023 Jul 31;12(8):e230005. doi: 10.1530/EC-23-0005.

Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes.肥胖症和 2 型糖尿病患者的代谢参数、瘦素和 SGLT2 抑制剂恩格列净的临床研究。

Int J Mol Sci. 2023 Feb 23;24(5):4405. doi: 10.3390/ijms24054405.

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.对于射血分数轻度降低或保留的心力衰竭患者，是否到了将钠-葡萄糖协同转运蛋白2抑制剂列为I类推荐的时候？一项更新的系统评价和荟萃分析。

Front Cardiovasc Med. 2023 Feb 7;10:1046194. doi: 10.3389/fcvm.2023.1046194. eCollection 2023.

本文引用的文献

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.恩格列净对射血分数保留的心力衰竭患者心力衰竭恶化事件的影响：EMPEROR-Preserved 试验。

Circulation. 2021 Oct 19;144(16):1284-1294. doi: 10.1161/CIRCULATIONAHA.121.056824. Epub 2021 Aug 29.

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。

N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.

Empagliflozin and Major Renal Outcomes in Heart Failure.恩格列净与心力衰竭的主要肾脏结局

N Engl J Med. 2021 Oct 14;385(16):1531-1533. doi: 10.1056/NEJMc2112411. Epub 2021 Aug 27.

SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis.钠-葡萄糖协同转运蛋白2抑制剂与心血管及肾脏结局：一项荟萃分析和试验序贯分析

Heart Fail Rev. 2022 May;27(3):951-960. doi: 10.1007/s10741-021-10083-z. Epub 2021 Feb 23.

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.SGLT2 抑制剂与 2 型糖尿病患者心血管和肾脏结局的关联：一项荟萃分析。

JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511.

Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。

N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.

Redefining Heart Failure With a Reduced Ejection Fraction.重新定义射血分数降低的心力衰竭。

JAMA. 2019 Nov 12;322(18):1761-1762. doi: 10.1001/jama.2019.15600.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献